| 5.25 0.03 (0.57%) | 04-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.75 | 1-year : | 10.72 |
| Resists | First : | 7.49 | Second : | 9.18 |
| Pivot price | 5.67  |
|||
| Supports | First : | 4.76 | Second : | 3.96 |
| MAs | MA(5) : | 5.2 |
MA(20) : | 5.73 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -0.5  |
Signal : | -0.5 |
| %K %D | K(14,3) : | 25.7 |
D(3) : | 22.1 |
| RSI | RSI(14): 43.1 |
|||
| 52-week | High : | 33.9 | Low : | 2.2 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PLYX ] has closed above bottom band by 29.4%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 5.46 - 5.49 | 5.49 - 5.51 |
| Low: | 5 - 5.03 | 5.03 - 5.05 |
| Close: | 5.2 - 5.25 | 5.25 - 5.29 |
Polaryx Therapeutics, Inc., operates as a biotech company that develops small molecule therapeutics for lysosomal storage disorders and neurodegenerative disorders. Its pipeline includes PLX-100, a combination of PLX-200 and a supplement for late infantile neuronal ceroid lipofuscinosis (LINCL) and other forms of NCL; PLX-200, a repurposed drug that is used to treat other diseases in adults and children; and PLX-300, a drug isolated from an edible plant that activates PPARa, which enhances production of transcription factor EB. The company was founded in 2014 and is based in Paramus, New Jersey.
Wed, 08 Apr 2026
Polaryx Therapeutics, Inc. - Common Stock (NQ: PLYX - The Chronicle-Journal
Mon, 09 Feb 2026
Historical PLYX stock prices (quote) - Polaryx Therapeutics, Inc. Common Stock - StockInvest.us
Sun, 08 Feb 2026
PLYX Insider Trading (Polaryx Therapeutics, Inc. Common Stock stock) - StockInvest.us
Thu, 05 Feb 2026
Major holders report 48% ownership in Polaryx Therapeutics (PLYX) - Stock Titan
Wed, 04 Feb 2026
PLYX Price Today: Polaryx Therapeutics, Inc. Stock Price, Quote & Chart - mexc.com
Mon, 02 Feb 2026
Polaryx Therapeutics, Clinical-Stage Developer of Therapies for Lysosomal Storage Disorders, Files for Nasdaq Capital Market IPO - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 47 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 73 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 393 (K) |
| Shares Short P.Month | 217 (K) |
| EPS | -0.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.1 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -96.2 % |
| Return on Equity (ttm) | -193.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | -27.64 |
| PEG Ratio | 0 |
| Price to Book value | 52.5 |
| Price to Sales | 0 |
| Price to Cash Flow | -63.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|